UCARTCS1, the first allogenic T-Cell treatment for Multiple Myeloma, has been cleared by the FDA to begin Phase 1 trials.


Those suffering of Multiple Myeloma have reason for hope today, as the first treatment using allogenic genetically modified CAR t-cells has passed the Investigational New Drug process with the FDA, allowing Cellectis to proceed with Phase 1 trials.

The current approach to treating multiple myeloma requires the patient’s blood to be extracted and processed, using an expensive process and specialized equipment. The treatment can approach $100,000 USD, according to this summary of how CAR t-cell therapy currently works at curetoday.

Allogenically produced CAR t-cells skip the expensive stages of harvesting and processing cells from the patient, and this process is potentially far more economical and can produce more effective CAR-t cells in less time, leading to expanded access to treatment for multiple myeloma.

You can read more about this at cellectis’ press release.


Please enter your comment!
Please enter your name here